Personalising metformin therapy: A clinician's perspective

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 6, 2014, Pages 442-444

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; ANTIDIABETIC AGENT;

CLINICAL EFFECTIVENESS; DATA ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLYCEMIC CONTROL; HUMAN; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; PREDICTION; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; QUANTITATIVE TRAIT;

DIABETES MELLITUS, TYPE 2; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; QUANTITATIVE TRAIT, HERITABLE;

EID: 84901600766     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70064-6     Document Type: Note

References (9)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.
2. Scheen AJ, Paquot N Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 2013, 39:179-190.
3. Maruthur NM, Gribble MO, Bennett WL, et al. The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care 2014, 37:876-886.
4. Zhou K, Donnelly L, Yang J, et al. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol 2014, published online March 19. http://dx.doi.org/10.1016/S2213-8587(14)70050-6.
5. Scheen AJ, Van Gaal LF Combatting the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Encocrinol 2014, published online Feb 19. http://dx.doi.org/10.1016/S2213-8587(14)70004-X.
6. Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 2012, 35:446-454.
7. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011, 50:81-98.
8. Christensen MM, Brasch-Andersen C, Green H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011, 21:837-850.
9. Stocker SL, Morrissey KM, Yee SW, et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 2013, 93:186-194.